Soligenix Reports Q2 2025 Results and Advances Rare Disease Treatments
August 14, 2025 — Soligenix announces Q2 2025 results, showcasing progress in rare disease treatments. Key milestones include Phase 2a results for psoriasis and CTCL therapies. Learn more.